prikaz prve stranice dokumenta Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers
  Preuzmi
PDF 150.59 KB
Znanstveni rad - Izvorni znanstveni rad
Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers
Endocrine, 36 (2009), 1; 70-74. https://doi.org/10.1007/s12020-009-9186-y
Kaštelan, Darko; Dušek, Tina; Kraljević, Ivana; Polašek, Ozren; Giljević, Zlatko; Solak, Mirsala; Zupančić Šalek, Silva; Jelčić, Jozo; Aganović, Izet; Koršić, Mirko

Citirajte ovaj rad

Kaštelan, D., Dušek, T., Kraljević, I., Polašek, O., Giljević, Z., Solak, M. ... Koršić, M. (2009). Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine, 36. (1), 70-74. doi: 10.1007/s12020-009-9186-y

Kaštelan, Darko, et al. "Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers." Endocrine, vol. 36, br. 1, 2009, str. 70-74. https://doi.org/10.1007/s12020-009-9186-y

Kaštelan, Darko, Tina Dušek, Ivana Kraljević, Ozren Polašek, Zlatko Giljević, Mirsala Solak, Silva Zupančić Šalek, Jozo Jelčić, Izet Aganović i Mirko Koršić. "Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers." Endocrine 36, br. 1 (2009): 70-74. https://doi.org/10.1007/s12020-009-9186-y

Kaštelan, D., et al. (2009) 'Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers', Endocrine, 36(1), str. 70-74. doi: 10.1007/s12020-009-9186-y

Kaštelan D, Dušek T, Kraljević I, Polašek O, Giljević Z, Solak M, i sur.. Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine [Internet]. 08.2009. [pristupljeno 17.04.2024.];36(1):70-74. doi: 10.1007/s12020-009-9186-y

D. Kaštelan, et al., "Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers", Endocrine, vol. 36, br. 1, str. 70-74, Kolovoz 2009. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:887716. [Citirano: 17.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:887716
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers
AutorDarko Kaštelan
AutorTina Dušek
AutorIvana Kraljević
AutorOzren Polašek
AutorZlatko Giljević
AutorMirsala Solak
AutorSilva Zupančić Šalek
AutorJozo Jelčić
AutorIzet Aganović
AutorMirko Koršić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
OBJECTIVE: Hypercoagulability is a commonly described complication in patients with Cushing's syndrome. Recent clinical studies have indicated various abnormalities of coagulation and fibrinolysis parameters which may be related to that phenomenon. The aim of this study was to investigate the mechanisms underlying the hypercoagulable state in patients with Cushing's syndrome. ----- RESEARCH METHODS AND PROCEDURES: A wide range of serum markers involved in the processes of blood coagulation and fibrinolysis was measured in a group of 33 patients with Cushing's syndrome and 31 healthy controls. No participant was taking medication which could influence the result or had known diseases, except hypertension and diabetes, which could affect blood coagulation or fibrinolysis parameters. ----- RESULTS: Patients with Cushing's syndrome had higher levels of clotting factors II (P = 0.003), V (P < 0.001), VIII (P < 0.001), IX (P < 0.001), XI (P < 0.001) and XII (P = 0.019), protein C (P < 0.001), protein S (P < 0.001), C1-inhibitor (P < 0.001) and plasminogen activator inhibitor-1 (PAI-1) (P = 0.004). The activity of fibrinolytic markers, plasminogen (P < 0.001), antithrombin (P < 0.001) and antithrombin antigen (P = 0.001) was also increased in the patient group. ----- CONCLUSION: The study has demonstrated hypercoagulability in patients with Cushing's syndrome manifest as increased prothrombotic activity and compensatory activation of the fibrinolytic system. We propose the introduction of thromboprophylaxis in the preoperative and early postoperative periods, combined with a close follow-up in order to prevent possible thromboembolic events in patients with Cushing's syndrome.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaEndocrine
Brojčani podacivol. 36, br. 1, str. 70-74
p-ISSN1355-008X
DOIhttps://doi.org/10.1007/s12020-009-9186-y
URN:NBNurn:nbn:hr:105:887716
Datum objave publikacije2009-08
URL dokumentahttps://doi.org/10.1007/s12020-009-9186-y
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 11:49:31